October 23rd, 2014 by Chassin
We’ve recently focused on the latest medicines and research in the alopecia areata field. Interested in the latest science and findings?
Read the full articles here:
Sign up for weekly updates here.
February 15th, 2013 by Chassin
Research News: Of mice, humans and what’s new about mouse-model research methods.
February 5th, 2013 by Chassin
Explaining about research is one of the ways we like to educate about alopecia areata. Quite often recent news from research quarters to alopecia areata sufferers emphasizes that “genes have been discovered” or “genes have been located” or similar “genes identified” with other autoimmune conditions. We urge caution in assuming that this means better treatments or cures are right around the corner.
To keep expectations in perspective, take a look at a press release like this one from the NIH about DNA research. What we want to emphasize to our community today is how important it is to notice the small and indefinite qualifiers in articles about any kind of research such as: “may lead”, “should help” and “may relate”.
February 2nd, 2013 by admin
Take a read of a physician’s view about the way results are disclosed….or not. Learn about “fake fixes” and a cultural lack of transparency.
December 29th, 2009 by Chassin
Intralesional corticosteroid injections continue to be the standard treatment for adults with patchy alopecia < 50% scalp involvement. Filed in October 2009 (clinicaltrials.gov) and not yet recruiting, this study in Asia proposes to compare steroid injections with Botox injections and compare the results of hair regrowth.
Is there no limit to what will be tried?
December 4th, 2008 by Chassin
It was announced in a press release by Allergan Inc. on 12/3/08 that the drug Lumigan, currently approved to treat glaucoma, is close to FDA approval for cosmetic use as an eyelash growth enhancer for upper lashes – but don’t get excited if you have extensive loss due to AA. It had been discovered in clinical studies that a side effect in glaucoma patients was the growth of longer, darker and fuller lashes. The FDA posted a review of the drug on its Web site Wednesday ahead of a Friday review by an outside panel of medical experts. The advisory panel is being asked to vote on whether it thinks Latisse ( the proposed brand name) should be approved. The FDA usually follows its panels’ advice. If approved, the product would be the first FDA-approved product sold for eyelash enhancement.
Two pilot studies were done with alopecia areata volunteers at the University of California San Francisco using Lumigan or Xalatan on patients with greater than 50 percent eyelash loss and concluded that it was not effective. No study has yet been done on AA patients with less than 50 percent loss. These pilot studies were a joint effort of the UCSF departments of dermatology and opthalmology with principal investigators Drs. Price and Stamper.
And as with all drugs, there will be risks and the potential for serious side effects in some people.
Click here for FDA briefing documents.